Announcements
Projects
Orgs
Project

Join The Pharma Letter

Create your account and become a member of this amazing organization

About The Pharma Letter
0
Members
15
Articles

Create Your Account & Join

Personal Information
Account Information
Leave blank if you prefer not to use a username
Security
6 characters minimum
What happens when you join?
  • Your account will be automatically created and confirmed
  • You'll be immediately added to The Pharma Letter
  • You'll be signed in automatically
  • Organization admins will be notified of your membership
  • You can start participating right away!

Already have an account?

Sign In Join with Existing Account
Recent Content from The Pharma Letter
First pill for dengue - JNJ-1802 - shows promise - The Pharma Letter
Oct 23, 2023
A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost. British drugmaker GSK (LSE: GSK) has been working on the jab, dubbed M72, since it picked up rights to the candidate through its 2005 purchase of American biotech Corixa. While the vaccine has shown 54% effectiveness in a Phase II trial enrolling around ... - The Pharma Letter
Jun 29, 2023
Initial safety and immunogenicity results from a Phase III trial of Bavarian Nordic's (OMX: BAVA) chikungunya virus vaccine candidate have been announced. The candidate is known as PXVX0317. The company said that the study has already met its primary efficacy endpoints, with a strong induction of chikungunya virus neutralizing antibodies having been observed in 87% of those receiving the ... - The Pharma Letter
Jun 21, 2023